Impact Of Blood Disorders On The Hematocrit Test Devices Market: A Key Factor Shaping the Future of the Hematocrit Test Devices Market in 2025

What Are the Projections for the Size and Growth Rate of the Hematocrit Test Devices Market?
In the past few years, the market size for hematocrit test devices has seen robust growth. It is projected to expand from a value of $4.63 billion in 2024 to $4.95 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.9%. This significant growth during the historical period can be ascribed to heightened awareness about anemia, deficiencies in iron and vitamins, a spike in chronic disease cases, growth in government financial backing, and a rise in population.

The market size for hematocrit test devices is predicted to experience robust growth in the upcoming years, with an estimated increase to $6.37 billion by 2029 at a compound annual growth rate (CAGR) of 6.5%. The surge during the forecast period can be attributed to the rising incidence of anemia, increasing blood disorder cases, escalation in the elderly population, an enhanced focus on health and well-being, and growing demand for heart disease diagnosis tools. Key trends foreseen during this period encompass the emergence of state-of-the-art solutions, progression in medical technology, production of effective and innovative products, technological advancements in hematocrit test methodologies, and improvements within the healthcare sector.

What Are the Primary Growth Drivers for the Hematocrit Test Devices Market?
The rising incidence of blood-related diseases is anticipated to boost the expansion of the hematocrit test devices market. Blood disorders, which impact the various components of human blood such as red and white blood cells, platelets, and blood plasma, are on the increase due to factors such as genetic predispositions, environmental pollution, and lifestyle alterations. Hematocrit test devices are chiefly employed to calculate the volume percentage of red blood cells in the whole blood, which offers vital data about the patient's blood health. For example, a report by the American Cancer Society, a not-for-profit organization based in the US, predicted in January 2024 that there would be about 62,770 new cases of all types of leukemia in 2024 in the United States, resulting in a projected 23,670 fatalities. Out of these cases, roughly 20,800 fresh cases of acute myeloid leukemia (AML), mainly affecting adults, are predicted, with about 11,220 deaths linked to AML, almost exclusively in adult patients. Therefore, the rising cases of blood disorders are contributing to the growth of the hematocrit test devices market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15582&type=smp

Which Businesses Are at the Forefront of Hematocrit Test Devices Market Development?
Major companies operating in the hematocrit test devices market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare GmbH, Becton, Dickinson and Company (BD), Terumo Corporation, Beckman Coulter Inc., Mindray Medical International Limited, bioMérieux SA, Sysmex Corporation, Horiba Ltd., Nihon Kohden Corporation, Erba Mannheim, Heska Corporation, EKF Diagnostics Holding Plc., Nova Biomedical Corporation, Boule Diagnostics AB, Stanbio Laboratory Lp, Drucker Diagnostics, A. Menarini Diagnostics Srl, Sensa Core, Mikroscan Technologies Inc.

What Are the Latest Innovations in the Hematocrit Test Devices Market?
Leading firms in the hematocrit test device market are introducing cutting-edge products like complete blood count (CBC) hematology analyzers which offer calculated and detailed data on blood cells. A CBC hematology analyzer is an advanced device tasked with the evaluation and measurement of several elements in the blood, comprising red and white blood cells, as well as platelets. For example, Mindray Medical International Limited, a medical device firm based in China, released the BC-700 hematology analyzer series in March 2022. This includes both CBC and erythrocyte sedimentation rate (ESR) test capabilities. Accompanied by other models, BC-720, BC-760, and BC-780, the BC-700 analyzer is a part of a series designed to provide mid-volume labs with diagnostic technology on par with premium products. The BC-700 Series, a more compact variant of the BC-6000 Series, is based on the same platform and features Mindray's SF Cube 3D analysis technology. The SF Cube technology employs fluorescence and bi-angular laser scatter signals to scrutinize target cells in three dimensions.

How Is the Hematocrit Test Devices Market Segmented?
The hematocrit test devices market covered in this report is segmented -

1) By Product: Hematocrit Test Meter, Hematocrit Test Analyzer, Reagents And Consumables
2) By Application: Anemia, Polycythemia Vera, Congenital Heart Diseases, Other Applications
3) By End-User: Hospitals And Ambulatory Surgical Centers, Clinics, Diagnostic And Pathology Labs, Other End-Users

Subsegments:
1) By Hematocrit Test Meter: Handheld Hematocrit Meters, Portable Hematocrit Meters, Desktop Hematocrit Meters, Point-Of-Care Hematocrit Meters, Digital Hematocrit Meters, Battery-Powered Hematocrit Meters
2) By Hematocrit Test Analyzer: Automated Hematocrit Analyzers, Benchtop Hematocrit Analyzers, Semi-Automated Hematocrit Analyzers, Microhematocrit Analyzers, High-Throughput Hematocrit Analyzers, Compact Hematocrit Analyzers
3) By Reagents And Consumables: Hematocrit Test Strips, Hematocrit Pipettes And Capillaries, Blood Sample Collection Tubes For Hematocrit Testing, Quality Control Reagents For Hematocrit Testing, Calibration Standards For Hematocrit Devices, Disposable Test Kits And Consumables

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/hematocrit-test-devices-global-market-report

Where Is the Hematocrit Test Devices Market Growth Most Prominent?
North America was the largest region in the hematocrit test devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematocrit test devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Hematocrit Test Devices Global Market Report?

- Market Size Analysis: Analyze the Hematocrit Test Devices Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Hematocrit Test Devices Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Hematocrit Test Devices Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Hematocrit Test Devices Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15582

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.